Home > News

News

Wellbeing at the Bar22 May 2017Charlotte May QC was part of a panel of experts speaking at the Wellbeing Evening hosted by the Bar Representation Committee at Lincoln’s Inn on 8 May 2017. The panel discussion included advice about how to raise awareness of wellbeing issues and to use wellbeing resources to provide support in the workplace. The closing address […]
Glaxo Wellcome UK Ltd v. Sandoz Ltd [2017] EWCA Civ 33510 May 2017This appeal is in a large scale action for Trade Mark infringement and passing off brought by Glaxo against Sandoz in relation to respiratory inhalers. The UK action forms part of a series of international disputes concerning these pharmaceutical products. Glaxo owns an EU colour per se trade mark which is visually represented by a […]
Charlotte May speaks at the launch of the London Chapter of ChIPs hosted at the Supreme Court S4 May 2017Charlotte May QC was one of the panellists at the launch of the London Chapter of ChIPs hosted at the Supreme Court on Thursday 27 April. ChIPs is a non-profit organisation dedicated to advancing women in technology, law and policy. The launch of the London Chapter represents an important step in helping to realise the […]
(1) Sandoz Ltd (2) Hexal AG v (1) G.D. Searle LLC (2) Janssen Sciences Ireland UC [2017] EWHC 987 (Pat)3 May 2017Charlotte May QC and William Duncan represented the claimants in an action concerning the defendants’ supplementary protection certificate (SPC) for the drug darunavir (marketed as “Prezista”). The case raised a question about the correct application of article 3(a) of Regulation 469/2009/EC (the “SPC Regulation”) – which states that a product the subject of an SPC […]
Glaxo Wellcome UK Limited (T/A Allen & Hanburys), Glaxo Group Limited v Sandoz Limited, Sandoz International GMBH [2017] EWCA Civ 2276 April 2017Martin Howe QC and Iona Berkeley represented the Respondents, “Sandoz”, in Glaxo’s Appeal against the decision of HHJ Hacon refusing permission to join two additional defendants to its claim for passing off. Glaxo alleged passing off on the basis that Sandoz had marketed asthma inhalers similar to Glaxo’s ‘Seratide’ inhalers in the UK. Glaxo had […]